Durvalumab

The FDA approved two oncology therapies for treatment of certain patients with lung cancer or pancreatic cancer.

Lung Cancer Awareness Month, observed every November, is intended to educate the public about the potential causes and risk factors of the disease.

In this edition, single-fraction SBRT outcomes for central lung tumors, adjuvant durvalumab extends survival in limited-stage small cell lung cancer and more.

Adjuvant durvalumab significantly improved PFS and OS compared with placebo among patients with limited-stage small cell lung cancer, according to study results presented at ESMO Congress.

Concurrent administration of chemoradiation and immunotherapy did not improve survival for patients with limited-stage small cell lung cancer, according to a study presented at American Society for Radiation Oncology Annual Meeting.

Despite the incidence of endometrial cancer diagnosis increasing annually, several promising approaches for treatment and diagnosis of endometrial cancer have been approved or are in development.

Use of durvalumab before and after radical cystectomy improved outcomes for patients with muscle-invasive bladder cancer, according to results of the randomized phase 3 NIAGARA trial.

The FDA expanded the approval of durvalumab for lung cancer.

Today is World Lung Cancer Day.

Adjuvant durvalumab failed to improve outcomes compared with placebo for certain patients with early-stage lung cancer, according to the agent’s manufacturer.